Epidermal delivery

Ideal platform for delivering vaccines and immunological compounds.

P.L.E.A.S.E.® Professional creates evenly distributed micropores through to the epidermis or even deeper, into the upper dermis, if required. The dramatically increased skin permeability from this process of microporation enables specific forms of topically applied substances to penetrate much faster and more deeply into the targeted skin layer.

Due to its precise micropore control, P.L.E.A.S.E.® is ideal for allergy vaccine delivery. In collaboration with Biomay AG, an established mouse model of allergic asthma (recombinant grass pollen) was used to show proof of concept of epidermal recombinant grass pollen delivery.

Subcutaneous immunotherapy (SCIT) is a common practice to desensitise patients against allergens contained in e.g. dust mites, grass and tree pollen, dog hair, cat hair. A series of injections are administered to the patient over many months in order to achieve immunisation.

In recent years, sublingual immunotherapy (SLIT) has become an alternative treatment option.

Both treatment options have limitations with regard to convenience (painful injections), side effects and efficacy. Based on first animal data , P.L.E.A.S.E.® IT (Immunotherapy)  may represent an advantageous therapy option.

Results of animal in vivo tests show

  • transcutaneous Immunotherapy via P.L.E.A.S.E.® generated micropores equals SCIT in efficacy
  • Transcutaneous Immunotherapy induces a different systemic immune profile than SCIT
  • P.L.E.A.S.E.® IT induces a decrease of pro-inflammatory cytokines
  • SCIT induces an unwanted boost of Th2 cells